Bruker and Switzerland-based Biognosys announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. The Bruker-Biognosys collaboration is expected to create synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BRKR:
